Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapirolizumab pegol (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Registrational; Therapeutic Use
  • Acronyms PHOENYCS GO
  • Sponsors UCB Biopharma

    • Most Recent Events

    • 19 Nov 2024 According to a Lupus Therapeutics media release, Megan E.B. Clowse, M.D. is the principal investigator of the study. Participants from the PHOENYCS GO study will continue to be followed in a long-term open-label study.
    • 19 Nov 2024 Results presented in the UCB Media Release.
    • 19 Nov 2024 According to a Lupus Therapeutics media release, based on this trial, UCB and Biogen is initiating a second Phase 3 trial of dapirolizumab pegol, PHOENYCS FLY, in 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top